Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects.

abstract：INTRODUCTION:Small-cell lung cancer is an aggressive disease for which the mainstay of treatment is chemotherapy. Despite good initial responses most patients will relapse. Some will receive second-line therapy with clinical benefit, but for third-line chemotherapy there is little evidence to guide treatment decisions ...

journal_title：Clinical lung cancer

authors： Simos D,Sajjady G,Sergi M,Liew MS,Califano R,Ho C,Leighl N,White S,Summers Y,Petrcich W,Wheatley-Price P

更新日期：2014-03-01 00:00:00

abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...

journal_title：Clinical lung cancer

authors： Matikas A,Kentepozidis N,Georgoulias V,Kotsakis A

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without simultaneous integrated boost (SIB) on fluorodeoxyglucose-positron emission tomography (FDG-PET) positive areas (gross tumor volume [GTV]-PET) for patients ...

journal_title：Clinical lung cancer

authors： Fodor A,Broggi S,Incerti E,Dell'Oca I,Fiorino C,Samanes Gajate AM,Pasetti M,Cattaneo MG,Passoni P,Gianolli L,Calandrino R,Picchio M,Di Muzio N

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this hypothesis, we analyzed TP53 mutations and downregulation of p14(arf), a negative regulator of p53 activated by on...

journal_title：Clinical lung cancer

authors： Cortot AB,Younes M,Martel-Planche G,Guibert B,Isaac S,Souquet PJ,Commo F,Girard P,Fouret P,Brambilla E,Hainaut P,Soria JC

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS:We reviewed 187 patients with NSCLC pN1-N2 w...

journal_title：Clinical lung cancer

authors： Ito M,Yamashita Y,Tsutani Y,Misumi K,Harada H,Miyata Y,Okada M

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:In the present study we aimed to investigate whether the predominance of the lepidic component in tumors was associated with the outcome of postoperative adjuvant chemotherapy for stage I lung adenocarcinoma. PATIENTS AND METHODS:Charts for patients with pathological stage I lung adenocarcinoma were retrosp...

journal_title：Clinical lung cancer

authors： Sasada S,Miyata Y,Mimae T,Tsutani Y,Mimura T,Okada M

更新日期：2016-09-01 00:00:00

abstract：:Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib treatment in large, randomized monotherapy trials. In preclinical studies, gefitinib has shown additive and even supra-additive antitumo...

journal_title：Clinical lung cancer

authors： Hammond LA

更新日期：2003-09-01 00:00:00

abstract：:Multiple studies have confirmed the value of radiation therapy in limited-stage small-cell lung cancer. The appropriate dose of radiation and the optimal fractionation scheme, however, remain controversial. This article will examine the history of radiation therapy in the management of small-cell lung cancer. It will ...

journal_title：Clinical lung cancer

authors： Roof KS,Fidias P,Lynch TJ,Choi NC

更新日期：2003-05-01 00:00:00

abstract：:The identification of tumor biomarkers provides information on the prognosis and guides the implementation of appropriate treatment in patients with many different cancer types. In non-small cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification have already been used in the clinic. Howev...

journal_title：Clinical lung cancer

authors： Slavik T,Asselah F,Fakhruddin N,El Khodary A,Torjman F,Anis E,Quinn M,Khankan A,Kerr KM

更新日期：2014-11-01 00:00:00

abstract：:Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...

journal_title：Clinical lung cancer

authors： Holt GE,Disis ML

更新日期：2008-02-01 00:00:00

abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

journal_title：Clinical lung cancer

authors： Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Standard treatment for stage III non-small-cell lung cancer (NSCLC) is concurrent chemotherapy and radiation (chemo-RT). However, N3 stage IIIB disease portends a worse prognosis and the tolerability of chemo-RT in patients ≥70 years old is a concern. In this analysis, we evaluate the survival of patients wi...

journal_title：Clinical lung cancer

authors： Qin A,Lusk E,Daignault-Newton S,Schneider BJ

更新日期：2019-07-01 00:00:00

abstract：PURPOSE:This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received gemcitabine 3000 mg/m(2) intravenously over 30 minutes and paclitaxel 15...

journal_title：Clinical lung cancer

authors： Wozniak AJ,Belzer K,Heilbrun LK,Kucuk O,Gadgeel S,Kalemkerian GP,Venkatramanamoorthy R,Kraut MJ

更新日期：2007-03-01 00:00:00

abstract：:This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...

journal_title：Clinical lung cancer

authors： Vokes EE,Senan S,Treat JA,Iscoe NA

更新日期：2009-05-01 00:00:00

abstract：INTRODUCTION:Pneumonitis is one of the immune-related adverse events of programmed death 1 (PD-1) inhibitors that sometimes cause lethal outcomes. Although some recent reports have described PD-1 inhibitors as more effective in non-small-cell lung cancer (NSCLC) patients with immune-related adverse events than in those...

journal_title：Clinical lung cancer

authors： Fukihara J,Sakamoto K,Koyama J,Ito T,Iwano S,Morise M,Ogawa M,Kondoh Y,Kimura T,Hashimoto N,Hasegawa Y

更新日期：2019-11-01 00:00:00

abstract：INTRODUCTION:Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type...

journal_title：Clinical lung cancer

authors： Tamiya M,Kobayashi M,Morimura O,Yasue T,Nakasuji T,Satomu M,Kohei O,Takayuki S,Morishita N,Suzuki H,Sasada S,Okamoto N,Hirashima T,Kawase I

更新日期：2013-01-01 00:00:00

abstract：:Recent advances in cancer cell biology have led to the development of therapeutic agents that target pathways critical to the development and progression of disease. These so-called "targeted therapies" might offer patients a more tolerable alternative to traditional systemic chemotherapy that often achieves therapeut...

journal_title：Clinical lung cancer

authors： Eton DT,Yost KJ,Cella D

更新日期：2006-09-01 00:00:00

abstract：INTRODUCTION:To prospectively evaluate the frequency and spectrum of incidental findings (IF) in a 5-year lung cancer screening program with low-dose spiral computed tomography (CT) and to estimate the additional costs of their imaging workup incurred from subsequent radiologic follow-up evaluation. MATERIALS AND METH...

journal_title：Clinical lung cancer

authors： Priola AM,Priola SM,Giaj-Levra M,Basso E,Veltri A,Fava C,Cardinale L

更新日期：2013-03-01 00:00:00

abstract：:Bevacizumab is the first molecularly targeted agent associated with improved outcomes in combination with chemotherapy in previously untreated patients with non-small-cell lung cancer (NSCLC). The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to carboplatin and pacli...

journal_title：Clinical lung cancer

authors： Morgensztern D,Govindan R

更新日期：2008-03-01 00:00:00

abstract：:The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations ...

journal_title：Clinical lung cancer

authors： Sangha R,Lara PN Jr,Adjei AA,Baas P,Choy H,Gaspar LE,Goss G,Saijo N,Schiller JH,Vokes EE,Gandara DR

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Uni...

journal_title：Clinical lung cancer

authors： Cortellini A,Chiari R,Ricciuti B,Metro G,Perrone F,Tiseo M,Bersanelli M,Bordi P,Santini D,Giusti R,Grassadonia A,Di Marino P,Tinari N,De Tursi M,Zoratto F,Veltri E,Malorgio F,Garufi C,Russano M,Anesi C,Zeppola T,

更新日期：2019-07-01 00:00:00

abstract：INTRODUCTION:The effect of local therapy (LT) for oligoprogressive epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has not been well established. Forty-six patients with stage IIIB/IV EGFR-mutated NSCLC were treated by LT and continuing tyrosine kinase inhibitors (TKIs) for oligoprogr...

journal_title：Clinical lung cancer

authors： Qiu B,Liang Y,Li Q,Liu G,Wang F,Chen Z,Liu M,Zhao M,Liu H

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:The optimal timing of thoracic radiation therapy (RT) in relation to chemotherapy is unknown in the treatment of nonmetastatic small cell lung cancer (SCLC). We analyzed the National Cancer Data Base (NCDB) to assess the effect on overall survival (OS) of RT timing with chemotherapy for patients with SCLC. ...

journal_title：Clinical lung cancer

authors： Wong AT,Rineer J,Schwartz D,Becker D,Safdieh J,Osborn V,Schreiber D

更新日期：2017-03-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

journal_title：Clinical lung cancer

authors： Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

更新日期：2004-03-01 00:00:00

abstract：BACKGROUND:Patients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND METHODS:We reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung ca...

journal_title：Clinical lung cancer

authors： Nikitas J,DeWees T,Rehman S,Abraham C,Bradley J,Robinson C,Roach M

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

journal_title：Clinical lung cancer

authors： Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:We evaluated the tolerability and efficacy of nimotuzumab, a humanized IgG1 monoclonal anti-epidermal growth factor receptor antibody, with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small-cell lung cancer. PATIENTS AND METHODS:In this multicenter, single-arm, open-label...

journal_title：Clinical lung cancer

authors： Yamamoto N,Harada H,Okamoto I,Masuda N,Hayakawa K,Satouchi M,Soejima T,Nishio M,Kozuka T,Takeda K,Tanaka M,Seto T,Sasaki T,Tsubouchi H,Kakurai Y,Nishimura Y,Nakagawa K

更新日期：2020-12-26 00:00:00

abstract：BACKGROUND:The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties between mutant and wild-type EGFR have not been fully characterized. ...

journal_title：Clinical lung cancer

authors： Gong Z,Chen J,Cheng JN,Sun C,Jia Q,Diao X,Zhu B

更新日期：2018-09-01 00:00:00

abstract：:Both gemcitabine and carboplatin have demonstrated activity in advanced non small-cell lung cancer. The combination of gemcitabine and cisplatin has demonstrated equivalent or superior efficacy to other commonly used agents and two-drug combinations, and a recent Eastern Cooperative Oncology Group trial suggested that...

journal_title：Clinical lung cancer

authors： Masters GA

更新日期：2000-12-01 00:00:00

abstract：BACKGROUND:The purpose of this study was to assess the applicability of an annual low-dose computed tomography (CT) screening program for lung cancer in a single institution in Israel, which has a relatively lower prevalence of lung cancer compared with other Western countries, and to examine stage distribution of dete...

journal_title：Clinical lung cancer

authors： Shaham D,Breuer R,Copel L,Agid R,Makori A,Kisselgoff D,Goitein O,Izhar U,Berkman N,Heching N,Sosna J,Bar-Ziv J,Libson E

更新日期：2006-01-01 00:00:00